Recent advances of stimuli-responsive systems based on transition metal dichalcogenides for smart cancer therapy.

J Mater Chem B

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.

Published: April 2019

Stimuli-responsive systems, which can be used for temporally and spatially controllable therapeutic platforms, have been widely investigated in cancer therapy. Among a wide range of stimuli-responsive nanomaterials, transition metal dichalcogenides (TMDCs) have recently attracted great attention due to their large surface-to-volume ratio, atomic thickness, and other unique physicochemical properties. Thus, TMDCs are able to be responsive to various endogenous (e.g. acidic pH and overexpressed enzymes) or exogenous stimuli (e.g. light and magnetic). The majority of TMDC-based therapeutic platforms are triggered by near-infrared (NIR) light. However, due to the limited penetration of NIR light, novel strategies that are able to ablate deep-seated tumor tissues have emerged in recent years and have been applied to design multi-stimuli-responsive nano-systems. A comprehensive overview of the development of stimuli-responsive TMDC-based nanoplatforms for "smart" cancer therapy is presented to demonstrate a more intelligent and better controllable therapeutic strategy. Furthermore, the versatile properties of TMDCs and the typical responsive principles of certain stimuli-responsive platforms are discussed for a better understanding of selected examples in this review.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8tb03240hDOI Listing

Publication Analysis

Top Keywords

cancer therapy
12
stimuli-responsive systems
8
transition metal
8
metal dichalcogenides
8
controllable therapeutic
8
therapeutic platforms
8
properties tmdcs
8
nir light
8
advances stimuli-responsive
4
systems based
4

Similar Publications

Combination therapy, which involves using multiple therapeutic modalities simultaneously or sequentially, has become a cornerstone of modern cancer treatment. Graphene-based nanomaterials (GBNs) have emerged as versatile platforms for drug delivery, gene therapy, and photothermal therapy. These materials enable a synergistic approach, improving the efficacy of treatments while reducing side effects.

View Article and Find Full Text PDF

Importance: Evolving breast cancer treatments have led to improved outcomes but carry a substantial financial burden. The association of treatment costs with the cost-effectiveness of screening mammography is unknown.

Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards.

View Article and Find Full Text PDF

Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).

Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.

Design, Setting, And Participants: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013.

View Article and Find Full Text PDF

Canonical and noncanonical NOTCH signaling in the nongenetic resistance of cancer: distinct and concerted control.

Front Med

January 2025

Zhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Jiaxing, 314400, China.

Therapeutic resistance in cancer is responsible for numerous cancer deaths in clinical practice. While target mutations are well recognized as the basis of genetic resistance to targeted therapy, nontarget mutation resistance (or nongenetic resistance) remains poorly characterized. Despite its complex and unintegrated mechanisms in the literature, nongenetic resistance is considered from our perspective to be a collective response of innate or acquired resistant subpopulations in heterogeneous tumors to therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!